Home » Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study

Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study

July 11, 2011

Baxter International revealed positive results from a late-stage study of HyQ to treat primary immunodeficiency, whereby the rate of bacterial infection was much lower than the threshold level.
RTTNews

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

President Biden Issues Executive Order on U.S. Supply Chain

Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

The Revised ICH E8: A Guide to New Clinical Trial Requirements